Santis William F, Peters Craig A, Yalla Subbarao V, Sullivan Maryrose P
Division of Urology, Surgical Service, Veterans Affairs Boston Healthcare System, 1400 VFW Parkway, West Roxbury, MA 02132, USA.
J Urol. 2003 Jul;170(1):259-63. doi: 10.1097/01.ju.0000060848.61864.e1.
Although many aspects of ureteral physiology are well characterized, the exact mechanism of ureteral smooth muscle modulation has not been fully established. In other smooth muscle contractility is modulated by angiotensin II (AngII). We determined the presence of a local ureteral renin-angiotensin system and characterized the functional role of AngII in ureteral smooth muscle.
Reverse transcriptase-polymerase chain reaction was performed to determine the expression of angiotensinogen, renin, angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA. The presence of AngII in ureteral tissue was determined by immunohistochemistry. Human and pig ureteral smooth muscle strips were suspended in tissue baths to determine the effect of the AngII receptor antagonist losartan on the frequency and amplitude of spontaneous ureteral contractions. Electrical field stimulation was performed before and after exposure to losartan.
Angiotensinogen, renin, angiotensin-converting enzyme and angiotensin receptor subtype 1 mRNA expression was detected in human ureter. Immunoreactivity for AngII was demonstrated in smooth muscle bundles and blood vessels of the ureter. Losartan decreased the amplitude and frequency of spontaneous ureteral contractions as well as the contractile response to electrical field stimulation in a dose dependent manner.
Gene expression of AngII precursors and receptor, and localization of AngII in the ureter suggest the presence of a local renin-angiotensin system in the ureter. The effect of AngII receptor antagonist on contractile responses suggests that AngII modulates ureteral smooth muscle contractile function. Therefore, a local renin-angiotensin system may have an important role in ureteral function under physiological and pathological conditions.
尽管输尿管生理学的许多方面已得到充分表征,但输尿管平滑肌调节的确切机制尚未完全确立。在其他平滑肌中,血管紧张素II(AngII)可调节收缩性。我们确定了局部输尿管肾素-血管紧张素系统的存在,并表征了AngII在输尿管平滑肌中的功能作用。
进行逆转录聚合酶链反应以确定血管紧张素原、肾素、血管紧张素转换酶和血管紧张素受体1型mRNA的表达。通过免疫组织化学确定输尿管组织中AngII的存在。将人和猪的输尿管平滑肌条悬于组织浴中,以确定AngII受体拮抗剂氯沙坦对输尿管自发收缩频率和幅度的影响。在暴露于氯沙坦之前和之后进行电场刺激。
在人输尿管中检测到血管紧张素原、肾素、血管紧张素转换酶和血管紧张素受体1型mRNA的表达。在输尿管的平滑肌束和血管中证实了AngII的免疫反应性。氯沙坦以剂量依赖性方式降低输尿管自发收缩的幅度和频率以及对电场刺激的收缩反应。
AngII前体和受体的基因表达以及AngII在输尿管中的定位表明输尿管中存在局部肾素-血管紧张素系统。AngII受体拮抗剂对收缩反应的影响表明AngII调节输尿管平滑肌收缩功能。因此,局部肾素-血管紧张素系统在生理和病理条件下可能对输尿管功能起重要作用。